Finerenone reduced risk of cardiovascular death by 14% and worsening heart failure events by 20% versus placebo in patients with heart failure with mildly reduced or preserved ejection fraction.
Does finerenone reduce cardiovascular events, renal disease progression, and heart failure hospitalizations in patients with HFmrEF/HFpEF, CKD, and type 2 diabetes?
Finerenone is an effective and safer non-steroidal MRA for managing HFpEF/HFmrEF and CKD, decreasing morbidity and mortality risks while limiting adverse effects like hyperkalemia.
Effect estimate: HR corresponding to 14% reduction in cardiovascular death and 20% reduction in worsening heart failure
In patients with type 2 diabetes and chronic kidney disease (CKD) heart failure with preserved ejection fraction is associated with considerable morbidity and it has fewer treatment options available. HFpEF, which is characterized by increased cardiovascular risks and poor outcomes, continues to be a therapeutic challenge, particularly in older persons. A non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone has excellent therapeutic potential in patients with HFpEF and CKD, notably those with diabetes type 2. Research indicate that Finerenone preferentially targets mineralocorticoid receptors associated with inflammation and fibrosis and that it also has an advantage over commonly used steroidal MRAs (e.g., spironolactone), which carry significant risks such as hyperkalemia, gynecomastia, and renal impairment. There are two phase 3 clinical trials namely FIDELIO-DKD and FIGARO-DKD demonstrating how effectively finerenone works in preventing the progression of renal damage and cardiovascular events in type 2 diabetic patients and in patients with CKD. In addition, the FINEARTS-HF study shows that hospitalizations for heart failure were reduced with use of finerenone and also the overall decline in individuals with HFpEF across all ages, particularly the older populations. Finally, Finerenone is found to be more appropriate for patients with complex medical histories because its safety profile shows fewer side effects compared to the traditional steroidal MRAs, as it has lower risks for electrolyte imbalances and renal function deterioration. This article addresses the safety, efficacy, mechanism of action, and various trials conducted on Finerenone and how it gained importance as an effective substitute in the management of HFpEF and CKD, decreasing morbidity and mortality risks while limiting adverse effects.
Faheem et al. (Sun,) conducted a review in Patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥ 40%) including elderly patients (n=6,001). Finerenone vs. Placebo was evaluated on Composite of cardiovascular death and overall deterioration of heart failure incidents (hospitalizations/urgent visits) (HR corresponding to 14% reduction in cardiovascular death and 20% reduction in worsening heart failure). Finerenone reduced risk of cardiovascular death by 14% and worsening heart failure events by 20% versus placebo in patients with heart failure with mildly reduced or preserved ejection fraction.